No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17029128.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
Medical subject headings
- Acetamides
- Anemia
- Anti-Bacterial Agents
- Oxazolidinones
- Pyridoxine
- Thrombocytopenia